Cargando…
Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
In selected patients with moderate to severe active ulcerative colitis who have failed to respond or are poorly responsive to standard pharmacologic forms of treatment with corticosteroids and immunosuppressive agents, therapy with a biological agent may be considered. While infliximab is an establi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826758/ https://www.ncbi.nlm.nih.gov/pubmed/24235838 http://dx.doi.org/10.2147/TCRM.S38852 |